Comments on: Cancerous Data? Novartis Statistics Whiz Blows The Whistle On Data Reporting System

By: On Pharma

On Pharma — Thu, 03 Jan 2008 20:57:52 +0000

[...] sales and marketing pecadillos the industry has seen so far this year, but it is a main theme in Mr. Olagunju’s complaints against Novartis and a recurring theme in 483s and regulatory [...]

By: On Pharma

On Pharma — Thu, 03 Jan 2008 20:57:34 +0000

[...] Peter Rost and Ed Silverman , who have both interviewed Mr. Olagunju, forÂ detailed reporting and analysis of theÂ case, but [...]

By: Hypocrisy rules

Hypocrisy rules — Tue, 31 Jul 2007 21:00:50 +0000

One ting you can beleive about the big pharma including this Co. They will do anything within reason in research and development to get where they want to go, have the drug on the market. That includes many other methods on top of strictly scientific and legal. Yes they are not killing those patients in trials and they are not producing drugs that border on poison but they are playing with fire too often. This comes easy for them for they are the Novartis Co and the players are taking the risk on their behalf and with their money. And they have plenty of it perhaps too plenty and they still want more.
Where they reallu stick it to us, is their promotional activity. Here they go all out, off label, fallse claims, bribes, payoffs, fake PMT. and so on. This on top of relentless “legal” promotions efforts that would include anything they deem useful like multiple sales forces, DTC ads,… you know the dril.
Can anyone stop them? Not “bloody likely” as someone said. Not in USA where they are so powerful and conected at top levels of our economic system. For them the dog eat dog capitalism works well.

By: Insider

Insider — Fri, 20 Jul 2007 18:30:21 +0000

Great job Ed and Peter.

Cheers

Jack

By: Lisa Van Syckel

Lisa Van Syckel — Fri, 20 Jul 2007 03:03:59 +0000

Did they distort or manipulate the data of their Ritalin Clinical trials?…..
Antipsychotics?……
Antidepressants?……